Cardio Diagnostics Holdings Announces Grant Of Patent In India; Under Number 484488 Titled "A Kit for Determining Methylation Status Of A CpG Dinucleotide And A Genotype Of A Single Nucleotide Polymorphism."
Portfolio Pulse from Benzinga Newsdesk
Cardio Diagnostics Holdings has been granted a patent in India, numbered 484488, for a kit that determines the methylation status of a CpG dinucleotide and a genotype of a single nucleotide polymorphism. The company now holds patents in multiple regions globally, including the United States, Europe, Australia, China, and Hong Kong, with additional patents pending worldwide.
January 08, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardio Diagnostics Holdings has been granted a new patent in India, which could strengthen its intellectual property position and potentially lead to increased market opportunities in the region.
The grant of a new patent typically has a positive impact on a company's stock as it can protect its technology, potentially reduce competition, and open up new market opportunities. Given that CDIO's patent is for a diagnostic kit, this could be significant for the company's product offerings and market expansion, especially in the healthcare and biotechnology sectors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100